- Home
- MTA vs SGP Comparison
MTA vs SGP Comparison
Compare MTA & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTA | SGP |
|---|---|---|
| Founded | 1983 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 902.2M | 799.4M |
| IPO Year | 2017 | 2026 |
Fundamental Metrics
Financial Performance| Metric | MTA | SGP |
|---|---|---|
| Price | $7.79 | $23.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $9.16 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 286.9K | 115.2K |
| Earning Date | 08-13-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $68.62 | N/A |
| Revenue Next Year | $67.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.95 | $17.06 |
| 52 Week High | $11.60 | $32.44 |
Technical Indicators
Market Signals| Indicator | MTA | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 27.13 | 38.08 |
| Support Level | $6.34 | $20.95 |
| Resistance Level | $7.97 | $25.83 |
| Average True Range (ATR) | 0.31 | 1.39 |
| MACD | -0.17 | -0.29 |
| Stochastic Oscillator | 3.54 | 21.85 |
Price Performance
Historical ComparisonAbout MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company that engages in the acquisition and management of precious metal and copper royalties and streams. It generates revenue from royalties, streams, and other interests. Geographically, the company generates revenue from Australia, Brazil, Mexico, and the USA.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.